PERTH, Australia – Chimeric Therapeutics Ltd. closed an IPO on the Australian Securities Exchange (ASX:CHM), raising AU$35 million (US$26.5 million) to fund its CAR T trial in glioblastoma.
BEIJING – Denovo Biopharma LLC closed a series D financing round to raise nearly ¥300 million (US$46 million), just six months after its $83.5 million series C round.
Scineuro Pharmaceuticals, based in Shanghai and Philadelphia, launched with a $100 million series A financing to focus on tackling central nervous system diseases. CEO Min Li told BioWorld the startup is “building a CNS portfolio through a combination of internal R&D and strategic collaborations.” Lilly Asia Ventures Fund and Arch Venture Partners co-led the round.
Clinical-stage biopharma HBM Holdings Ltd. (also known as Harbour Biomed) debuted on the Hong Kong Stock Exchange on Dec. 10, raising HK$1.71 billion (US$220.7 million) to advance its autoimmune candidates to commercial launches in 2023.
Nothing much has changed since last month. This year is still, by far, the best year for financings in biopharma history, although the gap between 2020 and the next highest year has widened even more.
Chinese biopharma Impact Therapeutics Inc. of Nanjing raised $50 million in a series C+ round on Nov. 30, two years after its $30 million series C round. Impact’s CEO Jun Bao told BioWorld that the majority of the proceeds would be used to take several programs forward. The financing round also paved the way toward an IPO.
HONG KONG – Olix Pharmaceuticals Inc. has raised ₩41.5 billion (US$37.90 million) to support the company’s U.S. expansion and advance its pipeline globally.
Biopharmas in Asia-Pacific raising money in public or private financings, including: Auris Medical, Burning Rock, Canbridge, ILC, I-Mab, Neuroglee, Olix, Perseus Proteomics, Sinovac, Sunshine.
Shenzhen Xbiome Biotech Co. Ltd., an artificial intelligence (AI)-based microbiome drugmaker, raised more than $20 million in a series B+ round, Xbiome CEO Yan Tan told BioWorld, financing that will help the company launch its phase I trial next year. It has been a year since the drugmaker closed a $14 million series B round. During this period, Tan said Xbiome submitted an IND to the FDA in October for its fecal microbiota transplant (FMT) capsule candidate, a potential treatment for graft-vs.-host disease.
RSS
